Continuous Bioprocessing and Perfusion Bioreactors

Sartorius AG, Merck Group, Lonza Group, Cytiva, Amgen Inc. and WuXi Biologics are among the companies active in the field. Their work includes process control, continuous-train technologies, inoculum production, cell-retention devices and downstream purification. Patent activity is also associated with Fujifilm Co., which leads the listed patent holders with 25 patents.

Enzene Biosciences Ltd, Meatable and Capra Biosciences Inc. are startups with relevant activity in the supplied facts. Enzene has patents for an integrated continuous therapeutic-protein system and ATF filter cleaning. Meatable has patented perfusion cell-culture methods for cultivated meat, while Capra applies modular continuous bioreactors to pharmaceutical ingredients and has received additional government support.

Sartorius AG, Merck Group, Cytiva, Amgen Inc. and Lonza Group are among the named suppliers and technology developers. Their activities span bioreactor and process-development platforms, cell-retention technologies, control strategies and perfusion methods. The facts also identify Thermo Fisher Scientific and Danaher Life Science among organizations active in integrated continuous trains and digital monitoring.

The Massachusetts Institute of Technology, East China University of Science and Technology and the Chinese Academy of Sciences are active research organizations in the field. Recent work includes MIT research on a regenerative perfusion bioreactor, a single-use high-density perfusion system developed at East China University of Science and Technology, and sensor and fermentation studies associated with the Chinese Academy of Sciences.

The facts list $94,996,707 in grants across 102 awards since 2020. These totals describe grants associated with the topic dataset and do not establish that every award directly funds continuous bioprocessing or perfusion bioreactor development. The broader funding-round entries should likewise be checked individually before treating them as direct sector investment.

Fujifilm Co. leads the listed patent holders with 25 patents. Amgen Inc. and Sartorius AG each have 9, followed by LanzaTech Inc. with 7. Genentech, Cytiva and Asahi Kasei Life Science Corporation each have 6 listed patents, while Boehringer Ingelheim has 5.

No: the facts report 386 patents in the 24-month window and a patent-growth change of -41.2%. Publication activity also declined, with publications in the last year down 5.4%. These indicators suggest a slowdown in recorded activity over the measured period, rather than proving that commercial adoption or investment has fallen at the same rate.

In August 2026, MIT researchers reported a regenerative perfusion bioreactor aimed at lowering media costs, and Merck & Co. researchers examined metabolic bottlenecks affecting glycosylation stability. In September 2026, Sartorius researchers reported nonlinear model-predictive control for CHO processes, while WuXi Biologics published an automated downstream purification strategy designed to work with continuous or batch upstream processing.

The main approaches are membrane-based cell retention, continuous microbial fermentation, integrated continuous trains, hybrid intensified processes, and digital control and monitoring. Membranes retain cells as media is exchanged; fermentation applies continuous operation to microbial production. Integrated trains connect process steps, while hybrid approaches mix operating modes. Digital tools monitor and adjust conditions, but depend on reliable sensors and process models.

Applications in the facts include therapeutic proteins, vaccines and viral vectors, cell and gene therapies, industrial biotechnology, and food and alternative proteins. Cell and gene therapies account for 1,479 associated documents, while therapeutic proteins account for 1,014. Recent work also explores perfusion for lentiviral vectors, continuous viral vaccine production and microbial manufacture of functional ingredients.